The London and Cambridge Technology team advised Endomag on its sale to Hologic for approximately $310 million.
Endomag is a developer of breast cancer surgery technologies based in Cambridge, UK.
Hologic, Inc. (Nasdaq: HOLX) is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnosis and treat health conditions and raise the standard of care around the world.
The transaction adds Endomag’s wireless breast surgery localization and lymphatic tracing solutions to Hologic’s breast surgery portfolio, providing breast surgeons and radiologists with an expanded range of options and enhanced user experience.
The Goodwin team was led by David Mardle, Adam Thatcher, Sarah Jordan, Heidi McNally and Duy Le.
For more details on the transaction, please see the press release.